Abstracts tagged "interleukins (IL)"

Abstract Number: 958 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Philip J Mease¹, Mark C. Genovese², Michael Weinblatt³, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Heikki T. Mansikka⁴, Amit Khatri⁴, Ahmed A. Othman⁴, Neil Wishart⁴, John Liu⁴ and Robert J. Padley⁴, ¹Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ²Stanford University Medical Center, Palo Alto, CA, ³Brigham and Women’s Hospital, Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Since inhibition of either Tumor Necrosis Factor (TNF) or interleukin 17 (IL-17) alone has demonstrated efficacy in psoriatic arthritis (PsA) on both joint and…
Abstract Number: 1126 • 2016 ACR/ARHP Annual Meeting
Interleukin-1 Is Not Involved in Synovial Inflammation and Cartilage Destruction in Collagenase-Induced Osteoarthritis
Stephanie van Dalen¹, Arjen Blom¹, Annet Sloetjes¹, Monique M. Helsen¹, Johannes Roth², Thomas Vogl², Wim B. van den Berg¹, Martijn van den Bosch¹ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Osteoarthritis (OA) is characterized by severe cartilage destruction, with a putative role for synovial macrophages. Up to 50% of the patients also show low…
Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1569 • 2016 ACR/ARHP Annual Meeting
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Noriyuki Seta², Keiko Yoshimoto¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan
Background/Purpose: The study enrolled 35 untreated RA patients and 14 healthy volunteers. DAS28-ESR was evaluated and peripheral blood samples were obtained at baseline and following…
Abstract Number: 1632 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Mark C. Genovese¹, Roy Fleischmann², Erin Mangan³, Janet van Adelsberg⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶, Chunpeng Fan⁷ and Tom WJ Huizinga⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Biostatistics, Sanofi Genzyme, Bridgewater, NJ, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy of sarilumab + MTX was demonstrated in patients with RA and inadequate response to MTX…
Abstract Number: 1633 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis
Désirée van der Heijde¹, Janet van Adelsberg², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez⁴, Erin Mangan⁵, Neil Graham⁵, Deborah Dukovic³, Alberto Spindler⁶ and Mark C. Genovese⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Sanofi Genzyme, Cambridge, MA, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Universidad Nacional Tucumán, Yerba Buena Tucuman, Argentina, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab + MTX demonstrated significant improvements in RA signs and symptoms, physical function, and inhibition of…
Abstract Number: 1661 • 2016 ACR/ARHP Annual Meeting
Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis
Tue Wenzel Kragstrup^1,2, Morten Nørgaard Andersen³, Berit Schiøttz-Christensen⁴, Anne Grethe Jurik⁵, Malene Hvid⁶ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Hospital Lillebaelt, Middelfart, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) involves activation of the innate immune system, inflammation and new bone formation. The innate immune system is activated through…
Abstract Number: 1715 • 2016 ACR/ARHP Annual Meeting
ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A, Does Not Provide Significantly Greater Efficacy Compared with Adalimumab in Subjects with Psoriatic Arthritis: Results from Exposure-Response Analyses
Ben Klunder¹, Amit Khatri², Mukul Minocha³, Paul Peloso⁴ and Ahmed A. Othman², ¹AbbVie, Ludwigshafen am Rhein, Germany, ²AbbVie Inc., North Chicago, IL, ³Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Laura C. Coates¹, Philip J Mease², Laure Gossec³, Bruce Kirkham⁴, Lawrence Rasouliyan⁵, Shephard Mpofu⁶, Steffen Jugl⁶, Chetan Karyekar⁷ and Kunal Gandhi⁷, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ³Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ⁴Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…
Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Anil Singh¹, Kayla O’Sullivan², Mukesh Chourasia³, Sadiq Umar⁴, Mahamudul Haque², Bhanupriya Madarampalli² and Salahuddin Ahmed², ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 2757 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
Iain B McInnes¹, Philip J Mease², Christopher T. Ritchlin³, Proton Rahman⁴, Alice B Gottlieb⁵, Bruce Kirkham⁶, Radhika Kajekar⁷, Evie Maria Delicha⁸, Luminita Pricop⁹ and Shephard Mpofu⁸, ¹University of Glasgow, Glasgow, Great Britain, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁵Tufts University School of Medicine, Boston, MA, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷One Health Plaza, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, significantly improved signs and symptoms of psoriatic arthritis (PsA) over 52 weeks (wks) in FUTURE 2 study (NCT01752634).1,2 Here…
Abstract Number: 69 • 2016 ACR/ARHP Annual Meeting
IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Michelle S.M.A. Damen¹, Rabia Agca², Suzanne Holewijn³, Jacqueline de Graaf¹, Jéssica C. Dos Santos^1,4, Piet L van Riel⁵, J Fransen⁶, Marieke J.H. Coenen⁷, Mike T. Nurmohamed⁸, M.G. Netea¹, Charles Dinarello⁹, L.A.B. Joosten¹, Bas Heinhuis¹ and Calin Popa¹⁰, ¹Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ³Rijnstate Ziekenhuis, Arnhem, Netherlands, ⁴Instituto de Patologia Tropical e Saúde Pública, Goiás, Brazil, ⁵Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ⁷Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, ¹⁰Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Patients with a chronic inflammatory disease such as rheumatoid arthritis (RA) are at higher risk of developing cardiovascular diseases (CVD). Interleukin (IL)-32 has previously…
Abstract Number: 3036 • 2016 ACR/ARHP Annual Meeting
IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production
Amara Ezeonyeji¹, Helen Baldwin², Milica Vukmanovic-Stejic³ and Michael R. Ehrenstein⁴, ¹Rheumatology, Medicine, University College London, London, United Kingdom, ²Rheumatology, Centre for Rheumatology Research, University College London, london, United Kingdom, ³Infection & Immunity, University College London, london, United Kingdom, ⁴Medicine, University College London, London, United Kingdom
Background/Purpose: IL-22 is an IL-10 family cytokine with both pro-inflammatory and anti-inflammatory effects and its dysregulation is associated with the development of autoimmune disease including…
Abstract Number: 646 • 2016 ACR/ARHP Annual Meeting
Population Pharmacokinetics of ABT-122, an Immunoglobulin Targeting Both TNF-α and IL-17A: Analyses Across Phase 1 Studies in Healthy Volunteers and Phase 2 Studies in Subjects with Rheumatoid or Psoriatic Arthritis
Amit Khatri and Ahmed A. Othman, AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-122 is a novel dual-variable domain immunoglobulin (DVD-IgTM), which specifically neutralizes both TNF alpha (TNFα) and interleukin-17A (IL-17). Drugs individually neutralizing TNFα or IL-17…
Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mark C. Genovese¹, Michael Weinblatt², Jacob A Aelion³, Heikki T. Mansikka⁴, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Ahmed A. Othman⁴, Amit Khatri⁴, Nasser S. Khan⁴ and Robert J. Padley⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³West Tennessee Research Institute, Jackson, TN, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].